Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported additional interim results from its ongoing phase I/II clinical study of its ChronVac-C® therapeutic DNA vaccine, which is delivered using Inovio’s electroporation-based DNA delivery system.

World Cup legend Sir Geoff Hurst, MBE, backed by leading doctors, MPs and patient groups today appealed for all men with prostate cancer to get access to the best care as it emerged 7 out of 10 with advanced disease do not receive chemotherapy despite being eligible for treatment.